Martin Shkreli
Judge rejects Martin Shkreli’s prison release request to work on COVID-19 therapy
May 18, 2020Sales and Marketing COVID-19, Martin Shkreli, coronavirus
Notorious incarcerated ex-pharma CEO Martin Shkreli has his request rejected to be released from prison in order to research a …
FDA approves first generic version of Shkreli-hiked toxoplasmosis drug Daraprim
March 2, 2020Sales and Marketing Cerovene, Daraprim, FDA, Martin Shkreli, generics, pharma
The FDA has awarded approval to the first generic medicine for the treatment of toxoplasmosis, authorising Cerovene’s version of Daraprim …
“Pharma Bro” Martin Shkreli charged by FTC for price fixing Daraprim
January 28, 2020Manufacturing and Production FTC, Martin Shkreli, New York Attorney General, Pharma Bro
Martin Shkreli, also known as the “Pharma Bro”, has been charged by the Federal Trade Commission for price fixing. The …
The April 2018 issue of Pharmafocus is now live!
March 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Martin Shkreli, Right to try, atrial fibrillation, falsified medicines directive, oncology, opioids, pharma
As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …
Top Ten most popular articles on Pharmafile.com this week
March 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten
Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for …
Martin Shkreli sentenced to seven years in jail for securities fraud
March 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma
Three years after he became “the most hated man in America” overnight for jacking up the price of life-saving HIV-related …
Martin Shkreli ordered to forfeit $7.36m ahead of fraud sentencing
March 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma
Reviled pharma bro Martin Shkreli is experiencing another heavy dose of karma after a US judge ordered him to forfeit …
‘Pharma bro’ Shkreli heads to jail
September 14, 2017Medical Communications Martin Shkreli, Shkreli, biotech, drugs, pharma, pharmaceutical
Martin Shkreli’s habit of being unable to stay out of the headlines continues, although this time with the repercussion that …
‘He was born this way’, Shkreli case becomes circus
June 29, 2017Medical Communications Martin Shkreli, Shkreli, Turing Pharmaceutical, turing
Martin Shkreli’s Attorney, Benjamin Brafman, defended his client in a bizarre reference to a pop singer, “As Lady Gaga would …
Price hiking: US pharma’s elephant in the room
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Martin Shkreli, Mylan, Sanofi, Turing Pharmaceuticals, price hikes
Mylan’s recent EpiPen price inflation scandal has reignited a seemingly never-ending debate on the power of drug companies to charge …
KaloBios cuts ties with former CEO Martin Shkreli, outlines ‘maniacal’ turnaround plan
August 30, 2016Research and Development, Sales and Marketing Daraprim, KaloBios, Martin Shkreli, Retrophin, benznidazole, turnaround
Two months after small drugmaker KaloBios returns from bankruptcy, controversial industry figure Martin Shkreli is no longer a stakeholder in …
KaloBios announces new affordable pricing model, refuses to engage in “price gouging”
April 12, 2016Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible
Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
Big pharma answers tough questions at US drug pricing hearing
February 5, 2016Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress
Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …
Martin Shkreli subpoenaed in US to testify over drug pricing
January 21, 2016Medical Communications, Sales and Marketing Daraprim, Howard Schiller, Martin Shkreli, Valeant, turing
Former pharma chief exec Martin Shkreli has been issued with a subpoena by the US House of representatives, compelling him …
KaloBios files for bankruptcy after Shkreli arrest
January 4, 2016Sales and Marketing KaloBios, Martin Shkreli
KaloBios has filed for bankruptcy in the wake of chief executive Martin Shkreli’s arrest on securities fraud charges last month …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
